Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
37 hedge funds and large institutions have $11.9M invested in Hepion Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 10 closing their positions.
274% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $409K
14% less funds holding
Funds holding: 43 → 37 (-6)
44% less capital invested
Capital invested by funds: $21.3M → $11.9M (-$9.36M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$72K |
| 2 |
AMC
Asset Management Corp
Northbrook,
Illinois
|
+$67.2K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$62.4K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$49.6K |
| 5 |
HF
HRT Financial
New York
|
+$40K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.3M |
| 2 |
Two Sigma Advisers
New York
|
-$1.2M |
| 3 |
ACM
Altium Capital Management
New York
|
-$883K |
| 4 |
Two Sigma Investments
New York
|
-$485K |
| 5 |
VF
Virtu Financial
New York
|
-$225K |
HEPA Hedge Fund Activity: Q3 2021 in Review
37 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2021, worth a combined $11.9M — down 44% from $21.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of HEPA and 5 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 7 added.
The largest buyer was Bank of New York Mellon, adding an estimated $72K. The largest seller was Ikarian Capital, cutting an estimated $1.3M.
- 37 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2021, down from 43 in Q2 2021.
- Funds reported $11.9M of Hepion Pharmaceuticals stock for Q3 2021, down 44% quarter-over-quarter.
- 5 funds opened new Hepion Pharmaceuticals positions in Q3 2021 and 10 closed out, a net change of -5 holders.
- The largest Hepion Pharmaceuticals buyer in Q3 2021 was Bank of New York Mellon, an estimated $72K added.
- The largest Hepion Pharmaceuticals seller in Q3 2021 was Ikarian Capital, an estimated $1.3M sold.
Based on aggregated 13F filings for Q3 2021.